Evidence map›Paper›PMID 26556362›Full record

ArticleViruses2015

Composite Sequence-Structure Stability Models as Screening Tools for Identifying Vulnerable Targets for HIV Drug and Vaccine Development.

Siriphan Manocheewa, John E Mittler, Ram Samudrala, James I Mullins

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Bioinformatics and Drug Discovery.Current topics in medicinal chemistry · 2017
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Siriphan ManocheewaDepartment of Microbiology, University ofWashington, Seattle,WA 98195-8070, USA. manocs@uw.edu.
John E MittlerDepartment of Microbiology, University ofWashington, Seattle,WA 98195-8070, USA. jmittler@uw.edu.
Ram SamudralaDepartment of Microbiology, University ofWashington, Seattle,WA 98195-8070, USA. ram@compbio.org.
James I MullinsDepartment of Microbiology, University ofWashington, Seattle,WA 98195-8070, USA. jmullins@uw.edu.
University of Washington · US

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI Kenneth Sherr · 1988 to 2026
$104.9M
Viral Determinants of HIV-1 Transmission in African HeterosexualsP01AI057005 · NIAID · UNIVERSITY OF WASHINGTON · PI LINGAPPA, JAIRAM RAO · 2003 to 2014
$20.5M
Mechanisms of Formation and Persistence of Active HIV ReservoirsR01AI111806 · NIAID · UNIVERSITY OF WASHINGTON · PI MULLINS, JAMES IVAN · 2014 to 2018
$4.3M
Conserved Elements Therapeutic DNA Vaccine for HIVR01AI104679 · NIAID · UNIVERSITY OF WASHINGTON · PI FULLER, DEBORAH H., MULLINS, JAMES IVAN · 2013 to 2016
$3.9M
Role of proviral loci in HIV latencyR01AI125026 · NIAID · UNIVERSITY OF WASHINGTON · PI MULLINS, JAMES IVAN · 2016 to 2019
$3.4M
NOVEL PARADIGMS FOR DRUG DISCOVERY: COMPUTATIONAL MULTITARGET SCREENINGDP1LM011509 · NLM · UNIVERSITY OF WASHINGTON · PI SAMUDRALA, RAM · 2012 to 2014
$2.4M
NOVEL PARADIGMS FOR DRUG DISCOVERY: COMPUTATIONAL MULTITARGET SCREENINGDP1OD006779 · OD · UNIVERSITY OF WASHINGTON · PI SAMUDRALA, RAM · 2010 to 2011
$1.7M
NIAID NIH HHS 1P01 AI057005NIAID NIH HHS P01 AI057005NIAID NIH HHS P30 AI027757NIAID NIH HHS R01 AI104679NIAID NIH HHS R01 AI111806NIAID NIH HHS R01 AI125026NIH HHS DP1 OD006779NLM NIH HHS DP1 LM011509
6 · The paper itself

Abstract

Rapid evolution and high sequence diversity enable Human Immunodeficiency Virus (HIV) populations to acquire mutations to escape antiretroviral drugs and host immune responses, and thus are major obstacles for the control of the pandemic. One strategy to overcome this problem is to focus drugs and vaccines on regions of the viral genome in which mutations are likely to cripple function through destabilization of viral proteins. Studies relying on sequence conservation alone have had only limited success in determining critically important regions. We tested the ability of two structure-based computational models to assign sites in the HIV-1 capsid protein (CA) that would be refractory to mutational change. The destabilizing mutations predicted by these models were rarely found in a database of 5811 HIV-1 CA coding sequences, with none being present at a frequency greater than 2%. Furthermore, 90% of variants with the low predicted stability (from a set of 184 CA variants whose replication fitness or infectivity has been studied in vitro) had aberrant capsid structures and reduced viral infectivity. Based on the predicted stability, we identified 45 CA sites prone to destabilizing mutations. More than half of these sites are targets of one or more known CA inhibitors. The CA regions enriched with these sites also overlap with peptides shown to induce cellular immune responses associated with lower viral loads in infected individuals. Lastly, a joint scoring metric that takes into account both sequence conservation and protein structure stability performed better at identifying deleterious mutations than sequence conservation or structure stability information alone. The computational sequence-structure stability approach proposed here might therefore be useful for identifying immutable sites in a protein for experimental validation as potential targets for drug and vaccine development.

Indexed as

Conserved SequenceAIDS VaccinesAnti-HIV AgentsComputational BiologyDrug DiscoveryHIV-1HIV AntigensHumansMass ScreeningProtein StabilityAIDS VaccinesAnti-HIV AgentsHIV Antigenscapsid protein (CA)destabilizing mutationsHIV-1point mutation modelingprotein structural stability predictiontolerated sequence space

Identifiers

PMID26556362
PMCPMC4664974
OpenAlexW2116627616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.